AN2 Therapeutics Finalizes $80M At-The-Market Offering, Enabling Substantial Dilution

summarizeSummary

AN2 Therapeutics has filed the final prospectus supplement for its $80 million At-The-Market (ATM) offering, enabling the sale of shares that could result in over 60% dilution for existing shareholders.

check_boxKey Events

• Highly Dilutive Capital Raise

  The full utilization of the $80 million ATM program, based on the April 17, 2026, stock price of $3.61 per share, could lead to the issuance of approximately 22.16 million shares. This represents a potential dilution of over 60% for existing shareholders, relative to the 35.95 million shares outstanding as of March 31, 2026.

• Proceeds for R&D and Operations

  The net proceeds from the offering are intended to fund research and development of product candidates, provide working capital, and support general corporate purposes, extending the company's financial runway.

auto_awesomeAnalysis

This 424B5 filing serves as the final prospectus supplement for AN2 Therapeutics' At-The-Market (ATM) equity offering, enabling the company to commence sales of up to $80 million in common stock through Jefferies LLC. While the establishment of this ATM program was previously announced on April 9, 2026, this filing operationalizes the program, allowing for the actual issuance of shares. The potential sale of the full $80 million, based on the April 17, 2026, price of $3.61 per share, could result in the issuance of approximately 22.16 million new shares. This represents a highly dilutive event for existing shareholders, potentially increasing the share count by over 60% compared to shares outstanding as of March 31, 2026. The proceeds are earmarked for critical research and development, working capital, and general corporate purposes, providing necessary capital runway but at a significant cost of dilution.